Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Leukocytes01:27

Disorders of Leukocytes

2.6K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
2.6K
Meiosis I01:49

Meiosis I

222.8K
Meiosis is a carefully orchestrated set of cell divisions, the goal of which—in humans—is to produce haploid sperm or eggs, each containing half the number of chromosomes present in somatic cells elsewhere in the body. Meiosis I is the first such division, and involves several key steps, among them: condensation of replicated chromosomes in diploid cells; the pairing of homologous chromosomes and their exchange of information; and finally, the separation of homologous chromosomes by...
222.8K
Meiosis vs. Mitosis02:57

Meiosis vs. Mitosis

75.7K
Cell division is necessary for growth and reproduction in organisms. Mitosis aids cell growth and development by dividing somatic cells. In contrast, meiosis causes the division of germ cells and plays an essential role in sexual reproduction. Due to their unique functional requirements, mitosis and meiosis differ from each other in multiple aspects.
Before the start of mitosis and meiosis I, the cell synthesizes DNA, resulting in two homologous copies of each chromosome. DNA synthesis is...
75.7K
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

3.7K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
3.7K
Karyotyping01:17

Karyotyping

70.9K
Overview
70.9K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

2.8K
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting ribonucleotide reductase to enhance the antileukemic activity of gilteritinib against chemoresistant <i>FLT3</i>- internal tandem duplication acute myeloid leukemia.

ASPET discovery·2026
Same author

Development and Characterization of a Novel Congenital Acute Erythroid Leukemia Cell Line with Unique Features.

Cancers·2026
Same author

RPS19 and RPL5 haploinsufficient models reveal divergent ribosomal subunit controls of fetal hematopoiesis.

Nature communications·2026
Same author

Poorly Differentiated Signet-Ring Cell Gastroesophageal Carcinoma in a Child With No Detectable Genetic Predisposition: Report of a Rare and Highly Aggressive Tumor.

Pediatric blood & cancer·2026
Same author

The Good Cancer, the Barely Cancer, and the Incurable Cancer.

JAMA oncology·2026
Same author

Transient Abnormal Myelopoiesis in a Non-Down Syndrome Infant With Subsequent Evolution to Acute Myeloid Leukemia.

Pediatric blood & cancer·2026

Related Experiment Video

Updated: Apr 20, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

10.3K

Down syndrome preleukemia and leukemia.

Kelly W Maloney1, Jeffrey W Taub2, Yaddanapudi Ravindranath2

  • 1Center for Cancer & Blood Disorders, Children's Hospital Colorado, 13123 East 16th Avenue, B115, Aurora, CO 80045, USA.

Pediatric Clinics of North America
|December 2, 2014
PubMed
Summary
This summary is machine-generated.

Children with Down syndrome (DS) have unique leukemia profiles. Myeloid leukemia of Down syndrome (ML-DS) shows high survival, while acute lymphoblastic leukemia (ALL) in DS requires specialized trials and supportive care for better outcomes.

Keywords:
B-ALLDown syndromeGATA1LeukemiaMyeloid leukemia of Down syndromePreleukemiaTransient abnormal hematopoiesis/transient myeloproliferative disorder

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.8K
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.9K

Related Experiment Videos

Last Updated: Apr 20, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

10.3K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.8K
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.9K

Area of Science:

  • Pediatric Oncology
  • Hematology
  • Genetics

Background:

  • Children with Down syndrome (DS) present distinct biological and cytogenetic factors influencing leukemia treatment and prognosis.
  • Myeloid leukemia of Down syndrome (ML-DS) is often preceded by transient abnormal hematopoiesis (TAM) and is associated with favorable event-free survival (EFS) rates.

Purpose of the Study:

  • To highlight the unique characteristics of acute leukemias in children with Down syndrome.
  • To emphasize the need for specialized therapeutic strategies and supportive care for acute lymphoblastic leukemia (ALL) in DS patients.
  • To underscore the importance of clinical trial enrollment for improving leukemia-free survival in this population.

Main Methods:

  • Review of existing literature on pediatric leukemia in Down syndrome.
  • Analysis of treatment outcomes and survival data for ML-DS and ALL in DS.
  • Identification of key factors affecting EFS and overall survival.

Main Results:

  • ML-DS demonstrates high event-free survival, frequently following a preleukemic phase (TAM).
  • Acute lymphoblastic leukemia (ALL) in DS patients exhibits poorer EFS and overall survival compared to non-DS ALL.
  • Enrollment in therapeutic trials, including relapse protocols, is crucial for improving outcomes.

Conclusions:

  • Children with DS require tailored approaches for managing acute leukemias due to their unique disease biology.
  • Further research and clinical trials are essential to enhance leukemia-free survival and supportive care for ALL in DS.
  • Investigating novel therapeutic agents is critical for improving outcomes in pediatric leukemia associated with Down syndrome.